Back to top
more

YS Biopharma Co., Ltd. (YS)

(Delayed Data from NSDQ)

$0.98 USD

0.98
52,626

+0.02 (2.08%)

Updated May 21, 2024 03:59 PM ET

After-Market: $0.98 0.00 (0.00%) 6:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for YS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for YS Biopharma Co, Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 54 1 1 -99,999
Receivables NA 67 0 0 NA
Notes Receivable NA 0 0 0 NA
Inventories NA 27 0 0 NA
Other Current Assets NA 3 0 0 NA
Total Current Assets NA 151 1 1 NA
Net Property & Equipment NA 83 0 0 NA
Investments & Advances NA 0 200 200 NA
Other Non-Current Assets NA 0 0 0 NA
Deferred Charges NA 0 0 0 NA
Intangibles NA 11 0 0 NA
Deposits & Other Assets NA 3 0 0 NA
Total Assets NA 250 201 201 NA
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 NA
Accounts Payable NA 12 0 0 NA
Current Portion Long-Term Debt NA 28 0 0 NA
Current Portion Capital Leases NA 0 0 0 NA
Accrued Expenses NA 55 0 0 NA
Income Taxes Payable NA 0 0 0 NA
Other Current Liabilities NA 0 0 0 NA
Total Current Liabilities NA 96 0 0 NA
Mortgages NA 0 0 0 NA
Deferred Taxes/Income NA 3 0 0 NA
Convertible Debt NA 0 0 0 NA
Long-Term Debt NA 43 0 0 NA
Non-Current Capital Leases NA 0 0 0 NA
Other Non-Current Liabilities NA 1 13 20 NA
Minority Interest (Liabilities) NA 0 0 0 NA
Total Liabilities NA 144 213 20 NA
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 NA
Common Stock (Par) NA 0 200 200 NA
Capital Surplus NA 387 0 0 NA
Retained Earnings NA -273 -12 -19 NA
Other Equity NA -8 0 0 NA
Treasury Stock NA 0 0 0 NA
Total Shareholder's Equity NA 106 -12 181 NA
Total Liabilities & Shareholder's Equity NA 250 201 201 NA
Total Common Equity 0 106 -12 181 0
Shares Outstanding 93.00 93.00 9.10 NA NA
Book Value Per Share 0.00 1.14 -1.34 0.00 0.00

Fiscal Year End for YS Biopharma Co, Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,968 -99,963 43 54
Receivables NA 57 60 69 67
Notes Receivable NA NA NA 0 0
Inventories NA 25 30 25 27
Other Current Assets NA 3 5 2 3
Total Current Assets NA 117 130 139 151
Net Property & Equipment NA 79 78 78 83
Investments & Advances NA NA NA 0 0
Other Non-Current Assets NA NA NA 0 0
Deferred Charges NA 1 0 0 0
Intangibles NA 10 10 11 11
Deposits & Other Assets NA 5 4 4 3
Total Assets NA 213 224 234 250
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 0 0
Accounts Payable NA 11 12 10 12
Current Portion Long-Term Debt NA 60 25 24 28
Current Portion Capital Leases NA NA NA 0 0
Accrued Expenses NA 53 54 55 55
Income Taxes Payable NA NA NA 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 125 92 90 96
Mortgages NA NA NA 0 0
Deferred Taxes/Income NA 3 3 3 3
Convertible Debt NA NA NA 0 0
Long-Term Debt NA 18 50 48 43
Non-Current Capital Leases NA NA NA 0 0
Other Non-Current Liabilities NA 0 0 1
Minority Interest (Liabilities) NA NA NA 0 0
Total Liabilities NA 146 147 142 144
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 375 370 368 387
Retained Earnings NA -300 -285 -269 -273
Other Equity NA -8 -7 -7 -8
Treasury Stock NA NA NA 0 0
Total Shareholder's Equity NA 67 78 91 106
Total Liabilities & Shareholder's Equity NA 213 224 234 250
Total Common Equity 0 100,066 100,077 91 106
Shares Outstanding 93.00 93.00 93.00 93.00 93.00
Book Value Per Share 0.00 1,075.98 1,076.09 0.98 1.14